pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not ap
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
Quick answer
AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not applicable, healthy volunteers. NovaPharmaNews links 249 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (120), phase 2 (79), phase 1 (46).
Company snapshot
AstraZeneca maintains 249 tracked programs across Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not applicable, healthy volunteers, Chronic kidney disease (CKD) and hypertension., Metastatic Prostate Cancer, Locoregional Hepatocellular Carcinoma (HCC), Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN), Breast Cancer, Chro
- 249 active pipeline program(s) linked via ClinicalTrials.gov.
- 2 US patent(s) indexed to this assignee profile.
- 249 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for AstraZeneca. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Daiichi and AstraZeneca's Enhertu: Early Breast Cancer Breakthrough
- approval
FDA Approval for Datroway: Implications for Breast Cancer Treatment
- deal
AstraZeneca's Breast Cancer Pill and ADAP Deal Insights
- approval
Imfinzi Receives FDA Approval for Bladder Cancer Treatment
- approval
IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer
- approval
FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights
- approval
FDA Approves AstraZeneca's Imfinzi-BCG Combination for High-Risk NMIBC
- approval
ASCO26: AstraZeneca's Camizestrant Data Aims to Sway FDA Approval
- approval
FDA Delays Decision on AstraZeneca's Camizestrant Following Negative Adcomm Vote
- approval
AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer
- approval
Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients
- approval
FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
Recent coverage
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.
EMA backs datopotamab deruxtecan for advanced lung cancer
EMA action on datopotamab deruxtecan adds a key catalyst for lung cancer tracking, even as the program’s regulatory path differs by region. For BD teams, investors, and analysts, the story now centers on approval status, label scope, and the next clinical and filing milestones.
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for AstraZeneca.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for AstraZeneca.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is AstraZeneca?
-
Is AstraZeneca publicly traded?
-
What drugs does AstraZeneca develop or market?
-
What are the latest developments for AstraZeneca?
-
What therapeutic areas does AstraZeneca focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
AstraZeneca maintains 249 tracked programs across Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not applicable, healthy volunteers, Chronic kidney disease (CKD) and hypertension., Metastatic Prostate Cancer, Locoregional Hepatocellular Carcinoma (HCC), Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN), Breast Cancer, Chronic Heart Failure, Triple-negative Breast Cancer. Momentum score: 25/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: cambridge GB. Ticker: EBA8A89.
Pipeline programs
SODIUM CHLORIDE, MYCOPHENOLATE MOFETIL, GLUCOSE, Oleclumab, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion., Monalizumab, IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB — phase phase_3, status active. Indication: Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC). Next milestone: not disclosed (TBD).
TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion. — phase phase_3, status active. Indication: Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation. Next milestone: not disclosed (TBD).
PEMBROLIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN, INFLIXIMAB, PACLITAXEL, MYCOPHENOLATE MOFETIL, GEMCITABINE, Datopotamab deruxtecan, PACLITAXEL ALBUMIN-BOUND — phase phase_3, status active. Indication: Triple-negative Breast Cancer. Next milestone: not disclosed (TBD).
Anifrolumab, Anifrolumab Placebo — phase phase_3, status active. Indication: Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria. Next milestone: not disclosed (TBD).
Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo — phase phase_3, status active. Indication: Active Proliferative Lupus Nephritis. Next milestone: not disclosed (TBD).
AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f — phase phase_3, status active. Indication: Relapsed or Refractory Multiple Myeloma. Next milestone: not disclosed (TBD).
Irinotecan Accord, 20 mg/ml, koncentrat do sporządzania roztworu do infuzji, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cyramza 10 mg/ml concentrate for solution for — phase phase_3, status active. Indication: Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2. Next milestone: not disclosed (TBD).
Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p — phase phase_3, status active. Indication: Endometrial Cancer. Next milestone: not disclosed (TBD).
Placebo - film-coated tablets, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets — phase phase_3, status active. Indication: BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer. Next milestone: not disclosed (TBD).
Placebo is 0.9% (w/v) NaCl for injection and is to be provided by sites., IVX-A12 — phase phase_3, status active. Indication: Respiratory Syncytial Virus and Human Metapneumovirus. Next milestone: not disclosed (TBD).
Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung — phase phase_3, status active. Indication: Non-Small Cell Lung Cancer. Next milestone: not disclosed (TBD).
BAY 1841788, NUBEQA 300 mg film-coated tablets, Saruparib, ZYTIGA 250 mg tablets, Xtandi - 40 mg film-coated tablets, ZYTIGA 500 mg film-coated tablets, Placebo to match (PTM) tablets, Abiraterone Teva 500 mg film-coated tablets — phase phase_3, status active. Indication: Metastatic Castration-Sensitive Prostate Cancer (mCSPC). Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: EMA backs datopotamab deruxtecan, but lung cancer access remains unclear (2026-06-07).
Nova coverage: EMA backs datopotamab deruxtecan for advanced lung cancer (2026-06-07).
Nova coverage: AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint (2026-06-07).
Nova coverage: 5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis (2026-06-06).
Nova coverage: Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target? (2026-06-06).
Nova coverage: Owkin and AstraZeneca Enhance AI Collaboration for Drug Research (2026-06-04).
Nova coverage: AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma (2026-06-04).
Nova coverage: AstraZeneca's Camizestrant: Navigating Divergent Regulatory Paths for Breast Cancer Treatment (2026-06-03).
Registry facts
Registry profile: founded unknown; employees 79242; market cap n/a; revenue n/a; LEI 636700ITSLXVAJVLAY33; CIK n/a.
Company type: pharma; public/private: public. Data quality score: 0.833.
Catalyst calendar
Catalyst: Daiichi and AstraZeneca's Enhertu: Early Breast Cancer Breakthrough — type approval, date 2026-05-19.
Catalyst: FDA Approval for Datroway: Implications for Breast Cancer Treatment — type approval, date 2026-05-23.
Catalyst: AstraZeneca's Breast Cancer Pill and ADAP Deal Insights — type deal, date 2026-05-27.
Catalyst: IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer — type approval, date 2026-05-30.
Catalyst: Imfinzi Receives FDA Approval for Bladder Cancer Treatment — type approval, date 2026-05-30.
Catalyst: FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights — type approval, date 2026-06-01.
Catalyst: FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension — type approval, date 2026-06-02.
Catalyst: ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address — type approval, date 2026-06-02.
Catalyst: ASCO26: AstraZeneca's Camizestrant Data Aims to Sway FDA Approval — type approval, date 2026-06-02.
Catalyst: FDA Delays Decision on AstraZeneca's Camizestrant Following Negative Adcomm Vote — type approval, date 2026-06-02.
Competitive peers
Peer: AstraZeneca (overlap score 50.0).
Peer: BEONE MEDICINES AUS (overlap score 50.0).
Peer: Novartis India (overlap score 40.0).
Peer: Sunshine Guojian Pharmaceutical (overlap score 40.0).
Peer: HOFFMANN-LA ROCHE (overlap score 40.0).
Peer: Amgen (overlap score 39.2).
Peer: Eli Lilly and (overlap score 32.4).
Peer: ADC Therapeutics (overlap score 26.0).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.